EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 1, Issue 5, 2006, Pages 406-412

  Dubey, Sarita ^a   Stephenson, Patricia ^b,c   Levy, Donna E ^b   Miller, Judith A ^d   Keller, Steven M ^e   Schiller, Joan H ^f   Johnson, David H ^g   Kolesar, Jill M ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF WISCONSIN   (United States)

^g VANDERBILT UNIVERSITY   (United States)

Author keywords

Allele; Intron 1; Simple sequence repeat

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; GENOMIC DNA; TUMOR MARKER;

ADULT; ANALYZER; ARTICLE; BODY WEIGHT; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DINUCLEOTIDE REPEAT; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA EXTRACTION; DNA SEQUENCE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HISTOLOGY; HOMOZYGOSITY; HUMAN; INTRON; LOG RANK TEST; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SEQUENCE ANALYSIS; SIMPLE SEQUENCE REPEAT; SQUAMOUS CELL; AGED; DRUG ANTAGONISM; GENETICS; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DINUCLEOTIDE REPEATS; FEMALE; GENE FREQUENCY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 33846979362     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200606000-00005     Document Type: Article

References (25)

1. Jemal A, Siegel R, Murray T, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Schiller J, Adak S, Feins R, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer: results from an ECOG prospective randomized trial of postoperative adjuvant therapy (E3590, INT0015). J Clin Oncol 2001;19:448-457.
3. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2006;23:5900-5909.
4. Khuri FR, Lee JS, Lippman SM, et al. Modulation of proliferating cell nuclear antigen in the bronchial epithelium of smokers. Cancer Epidemiol Biomarkers Prev 2001;10:311-318.
5. Franklin WA, Veve R, Hirsch FR, et al. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002;29 (1 Suppl 4):3-14.
6. Selvaggi G, Scagliotti GV, Novello S, et al. Prospective evaluation of epidermal growth factor (EGFR) expression in completely resected non-small cell lung cancer (NSCLC): effects of EGFR on long-term follow up (Abstract 1345). Proc Am Soc Clin Oncol 2002;21:337a.
7. Hirsch FR, Varella-Garcia M, Bunn PA, et al. Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-3807.
8. McInerney JM, Wilson MA, Strand KJ, et al. A strong intronic enhancer element of the EGFR gene is preferentially active in high EGFR expressing breast cancer cells. J Cell Biochem 2001;80:538-549.
9. Liu W, Innocenti F, Chen P, et al. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 2003;9:1009-1012.
10. Gebhardt F, Zanker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999;274:13176-13180.
11. Buerger H, Gebhardt F, Schmidt H, et al. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor. Cancer Res 2000;60:854-857.
12. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small cell lung cancer. N Engl J Med 2000;343:1217-1222.
13. Brandt B, Hermann S, Straif K, et al. Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene. Cancer Res 2004;64:7-12.
14. Amador ML, Oppenheimer D, Perea S, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004;64:9139-9143.
15. Breiman L, Friedmand JH, Olshen RA, et al. Classification and Regression Trees. Belmont, CA: Wadsworth International Group, 1984.
16. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-137.
17. Kari C, Chan T, Rocha de Quadros M, Rodeck U. Targeting the epidermal growth factor receptor in cancer. Cancer Res 2003;63:1-5.
18. Andrulis IL, Bull SB, Blackstein ME, et al. Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998;16:1340-1349.
19. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
20. Fukuoka M, Kris M, Giaccone G, et al. Phase II trials of gefitnib ("Iressa", ZD1839): rapid and durable objective responses in patients with advanced non-small cell lung cancer (IDEAL 1 and IDEAL 2) (Abstract P615). Lung Cancer 2003;41 (Suppl 2):S247.
21. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
22. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
23. Haley J, Whittle N, Bennet P, et al. The human EGF receptor gene: structure of the 110 kb locus and identification of sequences regulating its transcription. Oncogene Res 1987;1:375-396.
24. Chi DD, Hing AV, Helms C, et al. Two chromosome 7 dinucleotide repeat polymorphisms at gene loci epidermal growth factor receptor (EGFR) and pro alpha 2 (I) collagen (COL1A2). Hum Mol Genet 1992;1:135.
25. McKay JA, Murray LJ, Curran S, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002;38:2258-2264.